Profound Medical (PROF) EBIT (2024 - 2026)

Profound Medical has reported EBIT for 3 years, with the latest figure at -$11.1 million in Q2 2026.

• On a quarterly basis, EBIT rose 19.85% year-over-year to -$11.1 million in Q2 2026; TTM through Jun 2026 was -$35.4 million, a 16.41% increase from a year earlier, with the FY2025 full-year figure at -$41.3 million, down 24.78% from the prior year.
• EBIT was -$11.1 million for Q2 2026 at Profound Medical, down from -$8.0 million in the prior quarter.
• The five-year high for EBIT was -$7.4 million in Q4 2025, with the low at -$13.8 million in Q2 2025.
• Average EBIT over 3 years is -$9.3 million, with a median of -$8.6 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: EBIT slumped 76.05% in 2025, then increased 28.17% in 2026.
• Over 3 years, EBIT stood at -$8.3 million in 2024, then rose by 11.7% to -$7.4 million in 2025, then sank by 50.17% to -$11.1 million in 2026.
• The last three EBIT figures came in at -$11.1 million (Q2 2026), -$8.0 million (Q1 2026), and -$7.4 million (Q4 2025), per Business Quant data.